Logo image of ABUS

ARBUTUS BIOPHARMA CORP (ABUS) Stock Fundamental Analysis

NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD

3.34  +0.1 (+3.09%)

After market: 3.34 0 (0%)

Fundamental Rating

4

Taking everything into account, ABUS scores 4 out of 10 in our fundamental rating. ABUS was compared to 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ABUS as it has an excellent financial health rating, but there are worries on the profitability. ABUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ABUS has reported negative net income.
In the past year ABUS has reported a negative cash flow from operations.
In the past 5 years ABUS always reported negative net income.
ABUS had a negative operating cash flow in each of the past 5 years.
ABUS Yearly Net Income VS EBIT VS OCF VS FCFABUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -53.09%, ABUS perfoms like the industry average, outperforming 45.25% of the companies in the same industry.
ABUS's Return On Equity of -71.81% is in line compared to the rest of the industry. ABUS outperforms 55.81% of its industry peers.
Industry RankSector Rank
ROA -53.09%
ROE -71.81%
ROIC N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ABUS Yearly ROA, ROE, ROICABUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABUS Yearly Profit, Operating, Gross MarginsABUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ABUS has more shares outstanding than it did 1 year ago.
ABUS has more shares outstanding than it did 5 years ago.
ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABUS Yearly Shares OutstandingABUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ABUS Yearly Total Debt VS Total AssetsABUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -3.89, we must say that ABUS is in the distress zone and has some risk of bankruptcy.
ABUS's Altman-Z score of -3.89 is in line compared to the rest of the industry. ABUS outperforms 45.60% of its industry peers.
ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.89
ROIC/WACCN/A
WACC10.3%
ABUS Yearly LT Debt VS Equity VS FCFABUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

ABUS has a Current Ratio of 8.15. This indicates that ABUS is financially healthy and has no problem in meeting its short term obligations.
ABUS has a better Current ratio (8.15) than 74.47% of its industry peers.
A Quick Ratio of 8.15 indicates that ABUS has no problem at all paying its short term obligations.
ABUS has a Quick ratio of 8.15. This is in the better half of the industry: ABUS outperforms 74.65% of its industry peers.
Industry RankSector Rank
Current Ratio 8.15
Quick Ratio 8.15
ABUS Yearly Current Assets VS Current LiabilitesABUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

ABUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.91%, which is quite good.
Looking at the last year, ABUS shows a very negative growth in Revenue. The Revenue has decreased by -65.99% in the last year.
Measured over the past years, ABUS shows a small growth in Revenue. The Revenue has been growing by 0.53% on average per year.
EPS 1Y (TTM)15.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)-65.99%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%-26.62%

3.2 Future

The Earnings Per Share is expected to grow by 24.05% on average over the next years. This is a very strong growth
Based on estimates for the next years, ABUS will show a very strong growth in Revenue. The Revenue will grow by 94.81% on average per year.
EPS Next Y41.01%
EPS Next 2Y28.23%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue Next Year12.12%
Revenue Next 2Y13.96%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ABUS Yearly Revenue VS EstimatesABUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ABUS Yearly EPS VS EstimatesABUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABUS Price Earnings VS Forward Price EarningsABUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABUS Per share dataABUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as ABUS's earnings are expected to grow with 23.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.23%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

ABUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (4/24/2025, 8:00:00 PM)

After market: 3.34 0 (0%)

3.34

+0.1 (+3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/bmo
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners55.36%
Inst Owner Change0.26%
Ins Owners0.95%
Ins Owner Change0.68%
Market Cap639.54M
Analysts81.82
Price Target5.36 (60.48%)
Short Float %6.43%
Short Ratio8.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.47%
Min EPS beat(2)6.73%
Max EPS beat(2)14.22%
EPS beat(4)3
Avg EPS beat(4)5.1%
Min EPS beat(4)-11.41%
Max EPS beat(4)14.22%
EPS beat(8)6
Avg EPS beat(8)7.23%
EPS beat(12)9
Avg EPS beat(12)9.8%
EPS beat(16)12
Avg EPS beat(16)9.46%
Revenue beat(2)0
Avg Revenue beat(2)-15.38%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-1.32%
Revenue beat(4)0
Avg Revenue beat(4)-19.75%
Min Revenue beat(4)-44.67%
Max Revenue beat(4)-1.32%
Revenue beat(8)1
Avg Revenue beat(8)-19.57%
Revenue beat(12)3
Avg Revenue beat(12)7.79%
Revenue beat(16)6
Avg Revenue beat(16)6.91%
PT rev (1m)0%
PT rev (3m)0.96%
EPS NQ rev (1m)-29.25%
EPS NQ rev (3m)-29.25%
EPS NY rev (1m)34.64%
EPS NY rev (3m)37.43%
Revenue NQ rev (1m)25.78%
Revenue NQ rev (3m)25.78%
Revenue NY rev (1m)33.42%
Revenue NY rev (3m)33.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 103.64
P/FCF N/A
P/OCF N/A
P/B 6.57
P/tB 6.57
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.03
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.09%
ROE -71.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.19%
Cap/Sales 2.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.15
Quick Ratio 8.15
Altman-Z -3.89
F-Score3
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)40.22%
Cap/Depr(5y)35.71%
Cap/Sales(3y)3.27%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y41.01%
EPS Next 2Y28.23%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue 1Y (TTM)-65.99%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%-26.62%
Revenue Next Year12.12%
Revenue Next 2Y13.96%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%
EBIT growth 1Y7.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.54%
OCF growth 3YN/A
OCF growth 5YN/A